Cowen and Company’s Immunovant IMVT Stock Holding History

Cowen and Company’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,500	Closed	-$6.04K	–	632
2023 Q3	$6.04K	Buy	+11,500	New	+$260K	﹤0.01%	516

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Cowen and Company's IMVT Position: Q1 2024 in Review

Cowen and Company sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 69,410 shares — an estimated $2.92M sold.

Cowen and Company first reported a position in IMVT in Q4 2022 and held it in 3 quarters. The position peaked at $22.2M in Q4 2022. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

Cowen and Company reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 69,410 Immunovant shares in Q1 2024, an estimated $2.92M.
Cowen and Company first reported a position in Immunovant in Q4 2022 and held it in 3 quarters.
Cowen and Company's Immunovant position peaked at $22.2M in Q4 2022.
209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.